Aptamer-modified polymeric materials for the binding of factors in a wound environment
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/74
A61P-017/02
C07K-007/06
A61L-015/32
A61L-015/42
A61L-015/44
C07K-014/78
출원번호
US-0458071
(2012-04-27)
등록번호
US-9382290
(2016-07-05)
발명자
/ 주소
Courage, James
Allen, Diwi
McNulty, Amy
Rycerz, Anthony
Carroll, Christopher
Hanson, Douglas
Fruchterman, Todd
출원인 / 주소
KCI LICENSING, INC.
대리인 / 주소
Harness, Dickey & Pierce, P.L.C.
인용정보
피인용 횟수 :
0인용 특허 :
90
초록▼
The present invention provides aptamer-modified polymers and materials thereof, which may be used for the binding of factors in a wound bed. For example, the aptamer-modified materials can be polypeptides conjugated to polymer foam materials. Such materials may be used, for example, for dressings, w
The present invention provides aptamer-modified polymers and materials thereof, which may be used for the binding of factors in a wound bed. For example, the aptamer-modified materials can be polypeptides conjugated to polymer foam materials. Such materials may be used, for example, for dressings, wound inserts, or pads.
대표청구항▼
1. A wound dressing comprising a polyurethane foam substrate, wherein the polyurethane foam substrate comprises a co-polymer, and wherein the co-polymer comprises: a polymer polymerized with an amino sugar, ora polymer polymerized with an aminoglycoside,wherein an aptamer is covalently attached dire
1. A wound dressing comprising a polyurethane foam substrate, wherein the polyurethane foam substrate comprises a co-polymer, and wherein the co-polymer comprises: a polymer polymerized with an amino sugar, ora polymer polymerized with an aminoglycoside,wherein an aptamer is covalently attached directly or via one or more linkers to a repeat unit of the co-polymer, and wherein the aptamer is a polypeptide having a sequence at least 90% identical to SEQ ID NO:1 or at least 90% identical to SEQ ID NO:2. 2. The wound dressing of claim 1, wherein the amino sugar is chitosan or glucosamine. 3. The wound dressing of claim 1, wherein the aminoglycoside is selected from the group consisting of neomycin, dibekacin, kanamycin, tobramycin, streptomycin, and gentamicin. 4. The wound dressing of claim 1, wherein the polymer foam substrate is a reticulated open-celled foam. 5. The wound dressing of claim 1, wherein the polymer foam substrate further comprises a substituted silyl-derived linker. 6. The wound dressing of claim 1, wherein the polypeptide is modified with an amino or carboxyl terminal Cys (Cysteine) residue. 7. The wound dressing of claim 1, wherein the polypeptide is modified with the linker AEEAc-Cys-NH2 at the amino or carboxyl terminus, wherein AEEAc is [2-(2-aminoethoxy)ethoxy]acetic acid. 8. The wound dressing of claim 1, wherein the amino or carboxyl terminus of the polypeptide is modified with a polyethylene glycol (PEG) spacer-cysteine residue. 9. The wound dressing of claim 1, wherein the aptamer is covalently attached to the polymer foam substrate through one or more linkers. 10. The wound dressing of claim 9, wherein the aptamer is covalently attached to the one or more linkers through a thioether linkage. 11. The wound dressing of claim 9, wherein the linker is an N-(e-Maleimidocaproyloxy) sulfosuccinimide ester-derived linker (EMCS-derived linker) or a sulfo-EMCS-derived linker. 12. The wound dressing of claim 9, wherein the linker is a substituted silyl-derived linker. 13. The wound dressing of claim 12, wherein the substituted silyl-derived linker is derived from aminoundecyltriethoxysilane or aminopropyldiisopropylethoxysilane. 14. The wound dressing of claim 1, wherein the aptamer is a polypeptide having a sequence at least 90% identical to SEQ ID NO: 1. 15. The wound dressing of claim 14, wherein the polypeptide is modified with an amino or carboxyl terminal Cys residue. 16. The wound dressing of claim 14, wherein the polypeptide is modified with the linker AEEAc-Cys-NH2 at the amino or carboxyl terminus. 17. The wound dressing of claim 14, wherein the amino or carboxyl terminus of the polypeptide is modified with a polyethylene glycol (PEG) spacer-cysteine residue. 18. The wound dressing of claim 14, wherein the polypeptide is covalently attached to the polymer foam substrate through one or more linkers. 19. The wound dressing of claim 18, wherein the polypeptide is covalently attached to the one or more linkers through a thioether linkage. 20. The wound dressing of claim 18, wherein the linker is an N-(e-Maleimidocaproyloxy) sulfosuccinimide ester-derived linker (EMCS-derived linker) or a sulfo-EMCS-derived linker. 21. The wound dressing of claim 18, wherein the linker is a substituted silyl-derived linker. 22. The wound dressing of claim 21, wherein the substituted silyl-derived linker is derived from aminoundecyltriethoxysilane or aminopropyldiisopropylethoxysilane. 23. The wound dressing of claim 14, wherein the wound dressing further comprises a granulocyte macrophage colony stimulating factor (GM-CSF). 24. The wound dressing of claim 1, wherein the polypeptide comprises a sequence at least 90% identical to SEQ ID NO: 2. 25. The wound dressing of claim 24, wherein the polypeptide is modified with an amino or carboxyl terminal Cys residue. 26. The wound dressing of claim 24, wherein the polypeptide is modified with the sequence AEEAc-Cys-NH2 at the amino or carboxyl terminus. 27. The wound dressing of claim 24, wherein the amino or carboxyl terminus of the polypeptide is modified with a polyethylene glycol (PEG) spacer-cysteine residue. 28. The wound dressing of claim 24, wherein the polypeptide is covalently attached to the polymer foam substrate through one or more linkers. 29. The wound dressing of claim 28, wherein the polypeptide is covalently attached to the one or more linkers through a thioether linkage. 30. The wound dressing of claim 28, wherein the linker is an N-(e-Maleimidocaproyloxy) sulfosuccinimide ester-derived linker (EMCS-derived linker) or a sulfo-EMCS-derived linker. 31. The wound dressing of claim 28, wherein the linker is a substituted silyl-derived linker. 32. The wound dressing of claim 31, wherein the substituted silyl-derived linker is derived from aminoundecyltriethoxysilane or aminopropyldiisopropylethoxysilane. 33. The wound dressing of claim 24, wherein the wound dressing further comprises a vascular endothelial growth factor (VEGF). 34. The wound dressing of claim 1, wherein the aptamer is P16. 35. The wound dressing of claim 1, wherein the aptamer is P22. 36. The wound dressing of claim 1, wherein the polypeptide has the sequence of SEQ ID NO: 2. 37. A method for treating a wound comprising contacting a wound site with a wound dressing of claim 1. 38. The method of claim 37, wherein the method further comprises applying negative pressure to the wound site. 39. The method of claim 38, wherein the method further comprises applying wound instillation solution to the wound site. 40. A method for binding a growth factor, chemokine or cytokine comprising contacting a fluid comprising the growth factor, chemokine, or cytokine with a wound dressing of claim 1, thereby binding the growth factor, chemokine, or cytokine to the wound dressing. 41. The method of claim 40, further comprising contacting the wound dressing with at least a second fluid, wherein some or all of the growth factor, chemokine, or cytokine bound to the wound dressing is eluted into the second fluid.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (90)
Ward William J. (Hull GBX) Shorthouse Joanne (Hull GBX), Adhesive dressing for retaining a cannula on the skin.
Errede Louis A. (North Oaks MN) Stoesz James D. (St. Paul MN) Winter ; deceased George D. (late of St. Paul MN by Jenny Upton ; personal representative), Composite wound dressing.
Todd Robert J. (Salt Lake City UT) Yagge Jaime E. (Salt Lake City UT) Lowe James E. (Durham NC) Wonder Terry M. (Salt Lake City UT), Medical suction apparatus.
Ferdman Ariel (12 Hillside Ave. Melrose MA 02176) Kuo Jing-wen (Boxboro MA) Miller David (Brookline MA) Pinsky Vladimir (Brighton MA) Richards William D. (Medway MA) Swann David (Cambridge MA), Method and device for wound closure.
Moriuchi Yousuke (Fujinomiya JPX) Ishida Toshinobu (Fujinomiya JPX) Kousai Tadashi (Fujinomiya JPX), Method of securing a catheter body to a human skin surface.
Luheshi Abdul B. N. (Hull GB3) Smalley Robert K. (Urmston GB3) Kennewell Peter D. (Okus GB3) Westwood Robert (Kingston Bagpuize GB3), Process for the preparation of azabicyclo compounds.
Kashmer James S. (Budd Lake NJ) Klimbach John K. (Wayne NJ) Vendetti Randall P. (Lincoln Park NJ), Suction canister with unitary shut-off valve and filter features.
Richmond James W. (Kalamazoo MI) Tice Robert G. (Portage MI) Booth ; III William M. (Paw Paw MI), Vacuum wound drainage system and lipids baffle therefor.
McNeil Charles B. (5960 Arbour Ave. Edina MN 55436) McEvoy Thomas J. (13103 Baker Trail Minnetonka MN 55343), Wearable, variable rate suction/collection device.
Lock Peter M. (327 Lordswood La. Petrosa ; Walderslade ; Chatham ; Kent GB2) Webb David R. (9 Lambourn Way Lordwood ; Chatham ; Kent GB2), Wound dressing materials.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.